Wilhelm Haverkamp
Overview
Explore the profile of Wilhelm Haverkamp including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
226
Citations
4080
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ponikowski P, Friede T, von Bardeleben R, Butler J, Khan M, Diek M, et al.
J Am Coll Cardiol
. 2024 Sep;
84(24):2347-2363.
PMID: 39217574
Background: For patients with functional mitral regurgitation (FMR) and symptomatic heart failure (HF), randomized trials of mitral transcatheter edge-to-edge repair (M-TEER) have produced conflicting results. Objectives: This study sought to...
2.
Anker S, Friede T, von Bardeleben R, Butler J, Khan M, Diek M, et al.
N Engl J Med
. 2024 Aug;
391(19):1799-1809.
PMID: 39216092
Background: Whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation is uncertain. Methods: We conducted a randomized, controlled trial involving patients with heart failure...
3.
Strodthoff N, Lopez Alcaraz J, Haverkamp W
Eur Heart J Digit Health
. 2024 Jul;
5(4):454-460.
PMID: 39081937
Aims: Current deep learning algorithms for automatic ECG analysis have shown notable accuracy but are typically narrowly focused on singular diagnostic conditions. This exploratory study aims to investigate the capability...
4.
Anker S, Friede T, von Bardeleben R, Butler J, Khan M, Diek M, et al.
Eur J Heart Fail
. 2024 Jun;
26(7):1608-1615.
PMID: 38847420
Aim: The RESHAPE-HF2 trial is designed to assess the efficacy and safety of the MitraClip device system for the treatment of clinically important functional mitral regurgitation (FMR) in patients with...
5.
Wagner P, Mehari T, Haverkamp W, Strodthoff N
Comput Biol Med
. 2024 May;
176:108525.
PMID: 38749322
Deep neural networks have become increasingly popular for analyzing ECG data because of their ability to accurately identify cardiac conditions and hidden clinical factors. However, the lack of transparency due...
6.
Ott G, Schaubelt Y, Lopez Alcaraz J, Haverkamp W, Strodthoff N
PLoS One
. 2024 Apr;
19(4):e0302024.
PMID: 38603660
Cardiovascular diseases remain the leading global cause of mortality. Age is an important covariate whose effect is most easily investigated in a healthy cohort to properly distinguish the former from...
7.
Frohlich A, Porthun J, Talha K, Lena A, Hadzibegovic S, Wilkenshoff U, et al.
Clin Res Cardiol
. 2024 Apr;
PMID: 38587563
Background: Growth hormone (GH) resistance is characterized by high GH levels but low levels of insulin-like growth factor-I (IGF-I) and growth hormone binding protein (GHBP) and, for patients with chronic...
8.
Haverkamp W, Strodthoff N
Herzschrittmacherther Elektrophysiol
. 2024 Feb;
35(2):104-110.
PMID: 38361131
The use of artificial intelligence (AI) in healthcare has made significant progress in the last 10 years. Many experts believe that utilization of AI technologies, especially deep learning, will bring...
9.
Saussele S, La Rosee P, Kiani A, Haverkamp W, Jentsch-Ullrich K, Stegelmann F, et al.
Acta Haematol
. 2023 Oct;
147(3):344-351.
PMID: 37848002
Background: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML,...
10.
Haverkamp W, Tennenbaum J, Strodthoff N
Eur Heart J Digit Health
. 2023 Oct;
4(5):366-367.
PMID: 37794873
No abstract available.